MINI FUTURE OPTIONSSCHEIN - MODERNA | Market Closed - Börse Stuttgart 20:50:47 11/06/2024 BST | ||
| 5.58 EUR | -0.36% |
|
| Current month | -7.74% | ||
| 1 month | -33.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 5.58 | -0.36% |
| 10/06/24 | 5.6 | +5.86% |
| 07/06/24 | 5.29 | +6.01% |
| 06/06/24 | 4.99 | +1.01% |
| 05/06/24 | 4.94 | -15.12% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 08:50 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JK849F |
| ISIN | DE000JK849F7 |
| Date issued | 07/05/2024 |
| Strike | 208.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.48 € |
|---|---|
| Lowest since issue | 3.64 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
148.6
USD
Average target price
143.9
USD
Spread / Average Target
-3.13%
- Stock Market
- Certificates
- Certificat